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The purpose of this study was to clarify the relationship between the number of tumour-infiltrating T lymphocytes and the
clinicopathological features and clinical outcome in patients with non-small-cell lung cancer (NSCLC). Tissue specimens from 109
patients who underwent surgical resection for NSCLC were immunohistochemically analysed for CD4 and CD8 expression. Patients
were classified into two groups according to whether their tumours exhibited a ‘high’ or ‘low’ level of CD8
þ or CD4
þ lymphocyte
infiltration. Although the level of infiltration by CD8
þ T cells alone had no prognostic significance, the survival rate for patients with
both ‘high’ CD8
þ and ‘high’ CD4
þ T-cell infiltration was significantly higher than that for the other groups (log-rank test, P¼0.006).
Multivariate analysis indicated that concomitant high CD8
þ and high CD4
þ T-cell infiltration was an independent favourable
prognostic factor (P¼0.0092). In conclusion, the presence of high levels of both CD8
þ T cells and CD4
þ T cells is a significant
indicator of a better prognosis for patients with NSCLC, and cooperation between these cell populations may allow a significantly
more potent antitumour response than either population alone.
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Lung cancer is one of the most common malignancies in the
world, and despite remarkable advances in diagnosis and
treatment for the disease, the prognosis in most cases remains
poor. Non-small-cell lung cancer (NSCLC) represents about
75–80% of all lung cancers, and its overall 5-year survival rate is
less than 12–15% (Ihde, 1992; Non-small Cell Lung
Cancer Collaborative Group, 1995; Jemal et al, 2005). These facts
make clear the need for new parameters that will allow
better prognostic evaluation for this malignancy and more
reliable identification of patients likely to benefit from adjuvant
therapy.
In a variety of human solid cancers, tumour-infiltrating T
lymphocytes (TILs) are considered to play important roles in
anticancer immunomechanisms of the tumour-bearing host.
Among TILs, most CD8
þ T cells are cytotoxic T lymphocytes
that recognise particular tumour-associated antigens presented on
MHC class I molecules at the cancer cell surface and possess the
ability to destroy cancer cells directly. The favourable prognostic
significance of the presence of tumour-infiltrating CD8
þ T cells
was previously reported in a variety of cancers, including
colorectal cancer, oesophageal cancer, pancreatic cancer, bile duct
cancer and gallbladder cancer (Naito et al, 1998; Nakano et al,
2001; Schumacher et al, 2001; Cho et al, 2003; Nakakubo et al,
2003; Oshikiri et al, 2003; Fukunaga et al, 2004). In NSCLC,
however, the relationship between patient prognosis and the
presence of TILs is still obscure. The infiltration of natural killer
cells or macrophages into tumours was previously found to
indicate a favourable prognosis (Takeo et al, 1986; Takanami et al,
2001), whereas the presence of tumour-infiltrating CD8
þ T cells
was not found to be a predictor of patient survival (Mori et al,
2000; Wakabayashi et al, 2003).
CD4
þ T cells play a central role in orchestrating the immune
response to cancer. Essentially, CD4
þ T cells recognise peptides
presented on MHC class II molecules expressed primarily on
antigen-presenting cells. Although most tumour cells do not
express MHC class II molecules, CD4
þ T cells can effect an
antitumour response in the absence of CD8
þ T cells by secreting
cytokines, such as interferon-g (Mumberg et al, 1999; Qin and
Blankenstein, 2000), or by activation and recruitment of effector
cells such as macrophages and eosinophils (Greenberg, 1991; Hung
et al, 1998). However, the main role of CD4
þ T cells in the
immune response to cancer is to prime CD8
þ cells and maintain
their proliferation.
The purpose of the present study was to evaluate the infiltration
of CD4
þ and CD8
þ T cells by immunohistochemistry in order to
clarify the individual or synergistic role of TILs in NSCLC.
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Patients and tissue specimens
Tissue specimens from 109 patients who underwent surgical
resection for NSCLC between 1994 and 1996 in the Department of
Thoracic Surgery at Minami-Ichijo Hospital were studied. These
cases were histopathologically composed of 58 cases of adeno-
carcinoma, 40 of squamous cell carcinoma, seven of large cell
carcinoma, three of adeno-squamous cell carcinoma and one of
carcinosarcoma. Surgical resection was not performed in patients
presenting with distant site metastases. None of these patients
received either preoperative radiation or chemotherapy. Our series
included 71 men and 38 women with a mean age of 63 years (range
39–80). Follow-up data for each of these patients was collected for
at least 5 years, and 52 patients (48%) died during the follow-up
period. All specimens were fixed in 10% formalin and embedded in
paraffin wax. Unstained 4-mm sections were then cut from paraffin
blocks for immunohistochemical analysis. Histological classifica-
tion of tumours was based on the World Health Organization
criteria. All tumours were staged according to the pTNM
pathological classification of the UICC (International Union
Against Cancer) (Sobin and Wittekind, 1997).
Immunohistochemical examination
For immunohistochemical analysis, formalin-fixed and paraffin-
embedded sections were deparaffinised in xylene and rehydrated
through a graded series from ethanol to water. Endogenous
peroxidase activity was blocked by incubation in 3% hydrogen
peroxide for 10min. After washing in phosphate-buffered saline
(PBS, pH 7.4) twice, the sections were incubated with 10% normal
goat serum for 5min and then incubated overnight at 41C with the
primary antibodies at the following dilutions: anti-CD8 mouse
monoclonal antibody (C8/144B; DAKO, Glostrup, Denmark) 1:50,
anti-CD4 mouse monoclonal antibody (1F6; Novocastra, New-
castle, UK) 1:50. For negative controls, we used 10% normal
mouse serum in place of primary antibody. After three additional
washes, a biotinylated goat anti-mouse antibody (Histofine SAB-
PO kit; Nichirei Co., Tokyo, Japan) was applied at room
temperature for 30min. After the sections were washed in PBS
three times, freshly prepared 3,30-diaminobenzidine tetrahydro-
chloride (Histofine Simple stain DAB Solution; Nichirei Corpora-
tion, Tokyo, Japan) was used to visualise antibody binding and the
sections were washed in distilled water. Sections were counter-
stained with haematoxylin and mounted in Permount.
Evaluation and classification of CD8
þ and CD4
þ T cells
Tumour-infiltrating CD8
þ T cells were classified into two groups
by their location: CD8
þ T cells within cancer stroma adjacent to
cancer cell nests, or CD8
þ T cells within the cancer cell nests
themselves. For each group, we counted the number of CD8
þ T
cells with a magnification of  200 (Olympus Optical Co., Ltd,
Tokyo, Japan). The number of CD4
þ T cells in cancer stroma were
also counted and classified in the same way. Five areas containing
the highest abundance of TILs were evaluated in each case. All
counting was performed independently by three investigators of
this study without knowledge of the patients’ background or
outcome, and immunoreactivity in each section was represented
by the median scores.
Statistical analysis
Correlations between the numbers of both CD8
þ T cells and
CD4
þ T cells with the patients’ clinicopathological variables were
analysed by the w
2 test or Fisher’s exact probability test.
Correlation coefficient was described as r, and r40.7 was defined
as a strong correlation. Univariate analysis of the survival data was
performed using survival curves that applied the Kaplan–Meier
method with log-rank analysis. The influence of variables on
Figure 1 Representative immunohistochemical staining of NSCLC
tumour sections. (A) Adenocarcinoma (anti-CD8 antibody; original
magnification,  200). (B) Adenocarcinoma (anti-CD4 antibody,  200).
(C) Squamous cell carcinoma (anti-CD8 antibody,  200). (D) Squamous
cell carcinoma (anti-CD8 antibody,  400). Arrows indicate CD8-positive
stained lymphocytes.
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ssurvival was assessed using Cox multivariate regression analysis.
The risk ratio and its 95% confidence interval were recorded for
each marker. Probability values of less than 0.05 were considered
statistically significant in all analyses. All statistical analysis was
performed using StatView version 5.0 (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Immunohistochemistry and classification
Tumour-infiltrating T lymphocytes were predominantly observed
within the cancer stroma by immunohistochemical staining for
CD8 and CD4 (Figure 1). The number of infiltrating CD8
þ or
CD4
þ T cells in cancer stroma was overwhelmingly higher than
that within cancer nests.
Among 109 NSCLC specimens, the mean number of infiltrating
CD8
þ T cells in cancer stroma was 1527107 (median 148, range
6–566), that of CD8
þ T cells within cancer nests was 14725
(median 2, range 0–121) and that of CD4
þ T cells in cancer
stroma was 1697152 (median 134, range 0–626). The number of
CD8
þ T cells in the stroma and CD8
þ T cells within cancer nests
of individual cases are shown in Figure 2. There was no significant
correlation (r¼0.381; Po0.0001) between the number of CD8
þ T
cells in the stroma and the number of CD8
þ T cells within cancer
cell nests. We utilised the mean number of infiltrating cells as a
cutoff point to divide all tumours into groups as having either
‘high’ or ‘low’ infiltration by CD8
þ and CD4
þ cells in stromal and
in nest tissue. Fifty-three cases were classified as having ‘high’
(4151) levels of CD8
þ T-cell infiltration in stromal tissue and the
remainder as having ‘low’ (0–151) infiltration. Thirty-one cases
were classified as having ‘high’ (414) CD8
þ T-cell infiltration
within cancer nests and the remainder as having ‘low’ (0–14)
infiltration. Forty-four cases were classified as having ‘high’
(4168) CD4
þ T-cell infiltration within stroma and the remainder
as having ‘low’ (0–168) infiltration.
Relationships between CD8
þ TILs and clinicopathological
variables
The relationships between the levels of infiltration by CD8
þ T cells
in tumour stroma or nests and various clinicopathological features
are summarised in Table 1. Significant correlations with the
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Figure 2 The correlation between the number of CD8
þ T cells in
cancer stroma and within cancer cell nests in patients with NSCLC.
Table 1 Relationship between CD8
+ T-cell infiltration and clinicopathological features in NSCLC
CD8
+ T cells in cancer stroma CD8
+ T cells within cancer nests
Variables Low (n¼56) High (n¼53) P-value
a Low (n¼78) High (n¼31) P-value
a
Age (years)
o64 31 23 0.141 41 13 0.317
X64 25 30 37 18
Gender
Male 36 35 0.848 44 27 0.003
Female 20 18 34 4
pT classification
pT1 27 20 0.270 37 10 0.149
pT2–4 29 33 41 21
Lymph node metastasis
Negative 34 43 0.019 56 21 0.675
Positive 22 10 22 10
pTNM stage
I 29 38 0.033 51 16 0.183
II–III 27 15 27 15
Tumour grade
Poor 4 9 0.113 6 7 0.047
Other 52 44 72 24
Histological type
Squamous cell carcinoma 21 19 0.858 19 21 o0.0001
Other 35 34 59 11
aP-value was calculated by w
2 test or Fisher’s exact test. NSCLC¼non-small-cell lung cancer.
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þ T cells in cancer stroma were noted for lymph
node metastasis and pTNM stage (P¼0.019 and 0.033, respec-
tively). However, no significant correlations were found between
the number of CD8
þ T cells in cancer stroma and age, gender, pT
classification, histopathological grading and histological type. On
the other hand, the number of CD8
þ T cells within cancer cell
nests was significantly correlated with gender (P¼0.003), histo-
pathological grading (P¼0.047) and histological type (Po0.0001).
We also found that poorly differentiated tumours or squamous cell
carcinomas showed significantly higher numbers of CD8
þ T-cell
infiltration within cancer nests than did well-differentiated
tumours or tumours of other histological types. There was a
strong correlation between gender (males) and histological type
(squamous cell carcinoma) in the patient cohort of this study
(Po0.0001). No significant correlations were found between the
level of CD4
þ T-cell infiltration in cancer stroma and any of the
examined clinicopathological variables (data not shown).
Kaplan–Meier survival analysis
Kaplan–Meier analysis revealed that the level of CD8
þ T cells
within cancer nests or in cancer stroma or CD4
þ T cells in cancer
stroma independently had no significant relationship to the
survival of the patients. Survival curves constructed using the
Kaplan–Meier method are shown in Figure 3. Among the 109
patients of our study, no significant difference in survival was
observed between those with ‘high’ or ‘low’ levels of CD8
þ T cells
in cancer stroma (Figure 3A). Similarly, the level of stromal
infiltration by CD4
þ T cells demonstrated no prognostic
significance (Figure 3B). To evaluate the possibility that a high
level of both CD8
þ and CD4
þ T-cell infiltration in cancer stroma
might correlate with favourable patient prognosis, the patients
were classified into four groups: high-CD8
þ/high-CD4
þ T cells
(n¼26), high-CD8
þ/low-CD4
þ (n¼27), low-CD8
þ/high-CD4
þ
(n¼18) and low-CD8
þ/low-CD4
þ T cells (n¼38). The group that
exhibited both highCD8
þ and high CD4
þ T-cell infiltration in
cancer stroma demonstrated significantly higher survival rates
than the rest of the patients (log-rank test, P¼0.006; Figure 3C).
Multivariate analysis of CD8
þ/CD4
þ T cells and
clinicopathological variables
Multivariate analysis of the patients as grouped in the same way
was performed with other clinicopathological predictors for
survival time using the Cox regression model (Table 2). The
results indicated that high-CD8
þ/high-CD4
þ T cells infiltration in
cancer stroma was an independent favourable prognostic factor
(risk ratio, 3.221; P¼0.0092). Positive lymph node metastasis and
pT classification (pT2–4) also had independent unfavourable
prognostic values, with a risk ratio of 2.410 (P¼0.0036) and 4.502
(Po0.0001), respectively. Although histological type had prog-
nostic significance by univariate analysis, no significance was
observed by multivariate analysis.
DISCUSSION
In the immune response to cancer cells, tumour-infiltrating CD8
þ
T cells play an essential role, recognising tumour-associated
antigens presented on MHC class I molecules expressed on the
cancer cell surface and directly lysing cancer cells expressing the
same antigens. In previous immunohistochemical studies in a
variety of cancers, larger numbers of tumour-infiltrating CD8
þ T
cells usually signified a stronger immune reaction against the
cancer and indicated a better prognosis. In colorectal carcinomas,
the presence of large numbers of CD8
þ T cells within cancer cell
nests was a favourable independent prognostic factor (Naito et al,
1998), and a similar result was observed in oesophageal carcinoma
(Schumacher et al, 2001). Furthermore, we previously demon-
strated the prognostic significance of infiltrating CD8
þ T cells in
pancreatic cancer, gallbladder cancer, bile duct cancer and
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Figure 3 Kaplan–Meier analysis of overall survival according to (A) the
level of infiltration by CD8
þ T cells in cancer stroma, (B) the level of
infiltration by CD4
þ T cells in cancer stroma and (C) the simultaneous
presence of high levels of infiltrating CD8
þ T cells and CD4
þ T cells in
cancer stroma in patients with NSCLC. For details about the method of
classification, see Materials and Methods.
aHigh-CD8
þ/high-CD4
þ group
(n¼26) vs others (n¼83).
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soesophageal squamous cell carcinoma (Cho et al, 2003; Nakakubo
et al, 2003; Oshikiri et al, 2003; Fukunaga et al, 2004). However, in
NSCLC, the role of TILs for the survival of patients is still
controversial. Consistent with the previous results (Mori et al,
2000; Wakabayashi et al, 2003), the present study demonstrated
that neither CD8
þ T cells within cancer cell nests nor those in
cancer stroma had a significant impact on patient survival. The
reasons for this discrepancy were difficult to explain, because the
antitumour effect of CD8
þ T cells may be circumvented by various
mechanisms in the tumour cells. Tumour cells may obtain the
ability to evade immune surveillance by several strategies,
including a lack of adequate T-cell costimulation (Melero et al,
1997; Thomas et al, 1999), downregulation of cell-surface MHC
class I expression (Goodenow et al, 1985; Restifo et al, 1993;
Imboden et al, 2001), dysfunction of Fas (CD95/APO1)-mediated
apoptosis (Hahne et al, 1996; Strand et al, 1996) and secretion of
immunosuppressive factors, such as transforming growth factor-b
(Inge et al, 1992) or interleukin-10 (Fiorentino et al, 1991a,b).
Thus, the efficiency of the immune reaction against cancers can be
evaded by a variety of mechanisms used by tumour cells, and these
can vary, depending on the individual cancer. It will be worthwhile
to investigate the effect of such immuno-evasive factors on the
ability of CD8
þ T cells to mount an effective response against
tumour cells in NSCLC.
Despite the fact that we observed no prognostic significance of
high CD4
þ T-cell infiltration alone, we found a synergistic effect of
simultaneous high CD4
þ T-cell and CD8
þ T-cell infiltration in
cancer stroma as a favourable prognostic factor in NSCLC. In the
presence of a relatively high level of CD4
þ T-cell infiltration,
patients with a sufficient number of tumour-infiltrating CD8
þ T
cells demonstrated a significantly better prognosis. We have
previously demonstrated a similar synergistic effect between
tumour-infiltrating CD8
þ T cells and CD4
þ T cells in oesophageal
squamous cell carcinoma and pancreatic adenocarcinoma (Cho
et al, 2003; Fukunaga et al, 2004). The present study is the first
report demonstrating such an effect directly observed in resected
human specimens. This result suggests that cooperation between
infiltrating CD4
þ T cells and CD8
þ T cells in tumours might be
important in the suppression of the progression of NSCLC.
Previous studies have demonstrated that activation of CD4
þ T
cells is required for immunisation of CD8
þ T cells against cancer.
For activation and maintenance of tumour-infiltrating CD8
þ T
cells, CD4
þ T cells play an important role by secreting cytokines
such as interleukin-2, which is required for CD8
þ T-cell growth
and proliferation (Rosenberg et al, 1988, 1998; Yoshino et al, 1992;
Cheng et al, 1998; Wang and Rosenberg, 1999; Rosenberg, 2001;
Wang, 2001; Zeng, 2001). Reduction of CD4
þ T lymphocytes by
administration of anti-CD4 antibody allowed human lung cancer
xenografts to form orthotopically in immuno-competent mice
(Hunt et al, 2000). As CD4
þ T cells are necessary for the full
antitumour activity of CD8
þ T cells, this may explain why a high
level of CD8
þ T-cell infiltration alone in this study did not
correlate with a more favourable prognosis.
In the present study, we demonstrated that the level of CD8
þ T-
cell infiltration in cancer stroma correlated with pTNM staging and
the presence of lymph node metastasis. Although multivariate
analysis demonstrated that the presence of lymph node metastasis
was a significant independent unfavourable prognostic factor, this
result suggests that tumour-infiltrating CD8
þ T cells may not only
locally but also systemically suppress metastasis in lymph tracts.
Moreover, we found that the level of CD8
þ T-cell infiltration
within cancer cell nests had significant correlations with tumour
dedifferentiation and histological subtype in NSCLC, consistent
with previous reports (Mori et al, 2000; Wakabayashi et al, 2003).
One possible reason for these results is a difference in
immunogenicity of each subtype of cancer. In NSCLC, poorly
differentiated cancers or squamous cell carcinomas may express
larger amounts of tumour-associated antigens than other types of
cancers, and hence, the number of CD8
þ T cells within cancer cell
nests might reflect only the peculiarities of the cancer cells in small
locoregional areas. As the average number of CD8
þ T cells within
cancer cell nests was over 10-fold lower than that in cancer stroma
in the present data, CD8
þ T cells within cancer cell nests might
not have a significant influence on the immune response against
cancer due to the low level of antitumour immunity.
In conclusion, we found that infiltrating CD8
þ T cells and
CD4
þ T cells in NSCLC may cooperate to suppress cancer
progression and their presence together appears to be an
independent favourable prognostic factor in this disease. The
presence of both infiltrating CD8
þ T cells and CD4
þ T cells in
resected specimens may be a useful index for adjuvant therapies
for patients with poor prognosis.
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